Loading...
•
Jun 30, 2024
STERIS Q1 2025 Earnings Report
Announced financial results for fiscal 2025 first quarter, demonstrating revenue growth and strong segment performance.
Key Takeaways
STERIS reported an 8% increase in total revenue to $1.3 billion and a 6% growth in constant currency organic revenue. As reported EPS increased to $1.41, while adjusted EPS reached $2.03. The company reiterated its fiscal 2025 outlook, expressing confidence in achieving full-year guidance.
Total revenue from continuing operations increased by 8%, with constant currency organic revenue growing by 6%.
As reported EPS from continuing operations increased to $1.41, and adjusted EPS increased to $2.03.
Healthcare revenue grew by 10%, driven by improvements in consumable and service revenue.
Fiscal 2025 outlook has been reiterated, indicating continued confidence in delivering full-year guidance.
STERIS
STERIS
STERIS Revenue by Segment
STERIS Revenue by Geographic Location
Revenue by Segment
Healthcare Revenue
CapyFin.comAST Revenue
CapyFin.comLife Sciences Revenue
CapyFin.comRevenue by Geographic Location
Ireland Revenue
CapyFin.comUnited States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
STERIS continues to expect as reported revenue from continuing operations to increase 6.5-7.5%. Constant currency organic revenue from continuing operations is anticipated to increase 6-7%. Adjusted earnings per diluted share from continuing operations is anticipated to be in the range of $9.05 to $9.25. Capital expenditures are anticipated to be approximately $360 million and free cash flow is expected to be approximately $700 million.
Positive Outlook
- As reported revenue from continuing operations is expected to increase 6.5-7.5%.
- Currency is expected to be neutral to revenue in fiscal 2025.
- Constant currency organic revenue from continuing operations is anticipated to increase 6-7%.
- Adjusted earnings per diluted share from continuing operations is anticipated to be in the range of $9.05 to $9.25 compared with $8.20 in adjusted earnings from continuing operations in fiscal 2024.
- Free cash flow is expected to be approximately $700 million.
Challenges Ahead
- Total annual revenue for the divested business in fiscal 2024 was approximately $35 million which will be excluded from constant currency organic revenue growth from continuing operations in fiscal 2025.
- Capital expenditures are anticipated to be approximately $360 million.
- The fiscal 2025 outlook assumes an effective tax rate of approximately 23%.
- Uncertainties related to tax treatments under the TCJA and the IRA.
- The possibility that Pillar Two Model Rules could increase tax uncertainty and adversely impact STERIS's provision for income taxes and effective tax rate and subject STERIS to additional income tax in jurisdictions who adopt Pillar Two Model Rules.
Revenue & Expenses
Visualization of income flow from segment revenue to net income